ReviewRNA biology2026
miR-181a-5p: a key regulator of placental function in health and disease.
Review in RNA biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are essential post-transcriptional regulators implicated in diverse physiological and pathological processes. Recently, miR-181a-5p emerged as a critical modulator of placental function. This review synthesizes literature on miR-181a-5p at the maternal-foetal interface in normal pregnancies and complications, such as preeclampsia, gestational hypertension, gestational diabetes, and Rh-negative haemolytic disease of the foetus and newborn (Rh-HDFN). From a PubMed search, 12 articles were qualitatively synthesized. Evidence shows that early miR-181a-5p suppression is crucial for normal trophoblast proliferation via the renin-angiotensin system. Conversely, its aberrant expression characterizes gestational pathologies. In preeclampsia, miR-181a-5p upregulation suppresses trophoblast viability, migration, and invasion, increasing apoptosis. In gestational hypertension, its downregulation perturbs glycolytic metabolism. Furthermore, elevated miR-181a-5p disrupts endothelial and placental barriers in gestational diabetes and Rh-HDFN, respectively. Ultimately, miR-181a- as a pleiotropic regulator in the placenta. Decoding its molecular networks underscores its clinical potential as a biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.